nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Joint sprain—Dapsone—leprosy	0.067	0.067	CcSEcCtD
Methylphenidate—Ligament sprain—Dapsone—leprosy	0.0533	0.0533	CcSEcCtD
Methylphenidate—Application site reaction—Dapsone—leprosy	0.0287	0.0287	CcSEcCtD
Methylphenidate—Suicide attempt—Dapsone—leprosy	0.0237	0.0237	CcSEcCtD
Methylphenidate—Albuminuria—Dapsone—leprosy	0.018	0.018	CcSEcCtD
Methylphenidate—Hernia—Thalidomide—leprosy	0.0147	0.0147	CcSEcCtD
Methylphenidate—Grand mal convulsion—Thalidomide—leprosy	0.0145	0.0145	CcSEcCtD
Methylphenidate—Peripheral vascular disorder—Thalidomide—leprosy	0.014	0.014	CcSEcCtD
Methylphenidate—Skin exfoliation—Dapsone—leprosy	0.0128	0.0128	CcSEcCtD
Methylphenidate—Hostility—Thalidomide—leprosy	0.0124	0.0124	CcSEcCtD
Methylphenidate—Suicide attempt—Thalidomide—leprosy	0.0121	0.0121	CcSEcCtD
Methylphenidate—Platelet count decreased—Thalidomide—leprosy	0.0116	0.0116	CcSEcCtD
Methylphenidate—Toothache—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Methylphenidate—Psoriasis—Thalidomide—leprosy	0.011	0.011	CcSEcCtD
Methylphenidate—Nail disorder—Thalidomide—leprosy	0.0106	0.0106	CcSEcCtD
Methylphenidate—Psychotic disorder—Dapsone—leprosy	0.00954	0.00954	CcSEcCtD
Methylphenidate—Albuminuria—Thalidomide—leprosy	0.00923	0.00923	CcSEcCtD
Methylphenidate—Nasopharyngitis—Dapsone—leprosy	0.00873	0.00873	CcSEcCtD
Methylphenidate—Rash pustular—Thalidomide—leprosy	0.00864	0.00864	CcSEcCtD
Methylphenidate—Influenza—Dapsone—leprosy	0.00844	0.00844	CcSEcCtD
Methylphenidate—Petechiae—Thalidomide—leprosy	0.00837	0.00837	CcSEcCtD
Methylphenidate—Pancreatitis—Dapsone—leprosy	0.00828	0.00828	CcSEcCtD
Methylphenidate—Blood disorder—Thalidomide—leprosy	0.00825	0.00825	CcSEcCtD
Methylphenidate—Accidental injury—Thalidomide—leprosy	0.00778	0.00778	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Dapsone—leprosy	0.00771	0.00771	CcSEcCtD
Methylphenidate—Skin discolouration—Thalidomide—leprosy	0.00763	0.00763	CcSEcCtD
Methylphenidate—Bone disorder—Thalidomide—leprosy	0.00763	0.00763	CcSEcCtD
Methylphenidate—Thinking abnormal—Thalidomide—leprosy	0.00752	0.00752	CcSEcCtD
Methylphenidate—Drug interaction—Thalidomide—leprosy	0.00742	0.00742	CcSEcCtD
Methylphenidate—Dyskinesia—Thalidomide—leprosy	0.00733	0.00733	CcSEcCtD
Methylphenidate—Sinusitis—Dapsone—leprosy	0.00706	0.00706	CcSEcCtD
Methylphenidate—Neck pain—Thalidomide—leprosy	0.00697	0.00697	CcSEcCtD
Methylphenidate—Phosphatase alkaline increased—Thalidomide—leprosy	0.00689	0.00689	CcSEcCtD
Methylphenidate—Pharyngitis—Dapsone—leprosy	0.00671	0.00671	CcSEcCtD
Methylphenidate—Skin exfoliation—Thalidomide—leprosy	0.00658	0.00658	CcSEcCtD
Methylphenidate—Aplastic anaemia—Thalidomide—leprosy	0.00647	0.00647	CcSEcCtD
Methylphenidate—Dry eye—Thalidomide—leprosy	0.00636	0.00636	CcSEcCtD
Methylphenidate—Cramps of lower extremities—Thalidomide—leprosy	0.00633	0.00633	CcSEcCtD
Methylphenidate—Gynaecomastia—Thalidomide—leprosy	0.00616	0.00616	CcSEcCtD
Methylphenidate—Hyperkinesia—Thalidomide—leprosy	0.00601	0.00601	CcSEcCtD
Methylphenidate—Mental disability—Thalidomide—leprosy	0.00598	0.00598	CcSEcCtD
Methylphenidate—Euphoric mood—Thalidomide—leprosy	0.00592	0.00592	CcSEcCtD
Methylphenidate—Erythema—Dapsone—leprosy	0.00588	0.00588	CcSEcCtD
Methylphenidate—Lymphadenopathy—Thalidomide—leprosy	0.00586	0.00586	CcSEcCtD
Methylphenidate—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00575	0.00575	CcSEcCtD
Methylphenidate—Diabetes mellitus—Thalidomide—leprosy	0.00575	0.00575	CcSEcCtD
Methylphenidate—Photosensitivity—Thalidomide—leprosy	0.00569	0.00569	CcSEcCtD
Methylphenidate—Gastroenteritis—Thalidomide—leprosy	0.00564	0.00564	CcSEcCtD
Methylphenidate—Eczema—Thalidomide—leprosy	0.00556	0.00556	CcSEcCtD
Methylphenidate—Vision blurred—Dapsone—leprosy	0.00554	0.00554	CcSEcCtD
Methylphenidate—Eye pain—Thalidomide—leprosy	0.00554	0.00554	CcSEcCtD
Methylphenidate—Injury—Thalidomide—leprosy	0.00544	0.00544	CcSEcCtD
Methylphenidate—Libido decreased—Thalidomide—leprosy	0.00539	0.00539	CcSEcCtD
Methylphenidate—Increased appetite—Thalidomide—leprosy	0.00532	0.00532	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Thalidomide—leprosy	0.0053	0.0053	CcSEcCtD
Methylphenidate—Vertigo—Dapsone—leprosy	0.00528	0.00528	CcSEcCtD
Methylphenidate—Visual disturbance—Thalidomide—leprosy	0.00528	0.00528	CcSEcCtD
Methylphenidate—Cough—Dapsone—leprosy	0.00513	0.00513	CcSEcCtD
Methylphenidate—Hypoglycaemia—Thalidomide—leprosy	0.00512	0.00512	CcSEcCtD
Methylphenidate—Lethargy—Thalidomide—leprosy	0.0051	0.0051	CcSEcCtD
Methylphenidate—Cerebrovascular accident—Thalidomide—leprosy	0.0051	0.0051	CcSEcCtD
Methylphenidate—Diplopia—Thalidomide—leprosy	0.005	0.005	CcSEcCtD
Methylphenidate—Pain in extremity—Thalidomide—leprosy	0.005	0.005	CcSEcCtD
Methylphenidate—Disturbance in sexual arousal—Thalidomide—leprosy	0.00496	0.00496	CcSEcCtD
Methylphenidate—Affect lability—Thalidomide—leprosy	0.00492	0.00492	CcSEcCtD
Methylphenidate—Migraine—Thalidomide—leprosy	0.00492	0.00492	CcSEcCtD
Methylphenidate—Psychotic disorder—Thalidomide—leprosy	0.00488	0.00488	CcSEcCtD
Methylphenidate—Cardiac arrest—Thalidomide—leprosy	0.00475	0.00475	CcSEcCtD
Methylphenidate—Mood swings—Thalidomide—leprosy	0.00474	0.00474	CcSEcCtD
Methylphenidate—Tachycardia—Dapsone—leprosy	0.00468	0.00468	CcSEcCtD
Methylphenidate—Dehydration—Thalidomide—leprosy	0.00465	0.00465	CcSEcCtD
Methylphenidate—Liver function test abnormal—Thalidomide—leprosy	0.00462	0.00462	CcSEcCtD
Methylphenidate—Breast disorder—Thalidomide—leprosy	0.00452	0.00452	CcSEcCtD
Methylphenidate—Cramp muscle—Thalidomide—leprosy	0.0045	0.0045	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Thalidomide—leprosy	0.00441	0.00441	CcSEcCtD
Methylphenidate—Insomnia—Dapsone—leprosy	0.00434	0.00434	CcSEcCtD
Methylphenidate—Influenza—Thalidomide—leprosy	0.00432	0.00432	CcSEcCtD
Methylphenidate—Pancreatitis—Thalidomide—leprosy	0.00424	0.00424	CcSEcCtD
Methylphenidate—Angina pectoris—Thalidomide—leprosy	0.00421	0.00421	CcSEcCtD
Methylphenidate—Bronchitis—Thalidomide—leprosy	0.00416	0.00416	CcSEcCtD
Methylphenidate—Pancytopenia—Thalidomide—leprosy	0.0041	0.0041	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Thalidomide—leprosy	0.00402	0.00402	CcSEcCtD
Methylphenidate—Erectile dysfunction—Thalidomide—leprosy	0.00398	0.00398	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Thalidomide—leprosy	0.00394	0.00394	CcSEcCtD
Methylphenidate—Weight increased—Thalidomide—leprosy	0.00393	0.00393	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Dapsone—leprosy	0.00393	0.00393	CcSEcCtD
Methylphenidate—Weight decreased—Thalidomide—leprosy	0.00391	0.00391	CcSEcCtD
Methylphenidate—Pneumonia—Thalidomide—leprosy	0.00388	0.00388	CcSEcCtD
Methylphenidate—Infestation NOS—Thalidomide—leprosy	0.00385	0.00385	CcSEcCtD
Methylphenidate—Drowsiness—Thalidomide—leprosy	0.00385	0.00385	CcSEcCtD
Methylphenidate—Infestation—Thalidomide—leprosy	0.00385	0.00385	CcSEcCtD
Methylphenidate—Depression—Thalidomide—leprosy	0.00384	0.00384	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Thalidomide—leprosy	0.00382	0.00382	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Thalidomide—leprosy	0.0038	0.0038	CcSEcCtD
Methylphenidate—Body temperature increased—Dapsone—leprosy	0.00379	0.00379	CcSEcCtD
Methylphenidate—Abdominal pain—Dapsone—leprosy	0.00379	0.00379	CcSEcCtD
Methylphenidate—Myocardial infarction—Thalidomide—leprosy	0.00378	0.00378	CcSEcCtD
Methylphenidate—Conjunctivitis—Thalidomide—leprosy	0.00375	0.00375	CcSEcCtD
Methylphenidate—Sweating—Thalidomide—leprosy	0.00369	0.00369	CcSEcCtD
Methylphenidate—Haematuria—Thalidomide—leprosy	0.00367	0.00367	CcSEcCtD
Methylphenidate—Epistaxis—Thalidomide—leprosy	0.00363	0.00363	CcSEcCtD
Methylphenidate—Sinusitis—Thalidomide—leprosy	0.00361	0.00361	CcSEcCtD
Methylphenidate—Bradycardia—Thalidomide—leprosy	0.00352	0.00352	CcSEcCtD
Methylphenidate—Rhinitis—Thalidomide—leprosy	0.00347	0.00347	CcSEcCtD
Methylphenidate—Pharyngitis—Thalidomide—leprosy	0.00343	0.00343	CcSEcCtD
Methylphenidate—Urinary tract disorder—Thalidomide—leprosy	0.00342	0.00342	CcSEcCtD
Methylphenidate—Urethral disorder—Thalidomide—leprosy	0.00339	0.00339	CcSEcCtD
Methylphenidate—Visual impairment—Thalidomide—leprosy	0.00333	0.00333	CcSEcCtD
Methylphenidate—Erythema multiforme—Thalidomide—leprosy	0.00327	0.00327	CcSEcCtD
Methylphenidate—Eye disorder—Thalidomide—leprosy	0.00323	0.00323	CcSEcCtD
Methylphenidate—Cardiac disorder—Thalidomide—leprosy	0.00321	0.00321	CcSEcCtD
Methylphenidate—Angiopathy—Thalidomide—leprosy	0.00314	0.00314	CcSEcCtD
Methylphenidate—Immune system disorder—Thalidomide—leprosy	0.00312	0.00312	CcSEcCtD
Methylphenidate—Mediastinal disorder—Thalidomide—leprosy	0.00312	0.00312	CcSEcCtD
Methylphenidate—Chills—Thalidomide—leprosy	0.0031	0.0031	CcSEcCtD
Methylphenidate—Arrhythmia—Thalidomide—leprosy	0.00309	0.00309	CcSEcCtD
Methylphenidate—Alopecia—Thalidomide—leprosy	0.00306	0.00306	CcSEcCtD
Methylphenidate—Vomiting—Dapsone—leprosy	0.00305	0.00305	CcSEcCtD
Methylphenidate—Mental disorder—Thalidomide—leprosy	0.00303	0.00303	CcSEcCtD
Methylphenidate—Malnutrition—Thalidomide—leprosy	0.00301	0.00301	CcSEcCtD
Methylphenidate—Headache—Dapsone—leprosy	0.00301	0.00301	CcSEcCtD
Methylphenidate—Tension—Thalidomide—leprosy	0.00295	0.00295	CcSEcCtD
Methylphenidate—Nervousness—Thalidomide—leprosy	0.00292	0.00292	CcSEcCtD
Methylphenidate—Back pain—Thalidomide—leprosy	0.00291	0.00291	CcSEcCtD
Methylphenidate—Muscle spasms—Thalidomide—leprosy	0.00289	0.00289	CcSEcCtD
Methylphenidate—Nausea—Dapsone—leprosy	0.00285	0.00285	CcSEcCtD
Methylphenidate—Vision blurred—Thalidomide—leprosy	0.00284	0.00284	CcSEcCtD
Methylphenidate—Tremor—Thalidomide—leprosy	0.00282	0.00282	CcSEcCtD
Methylphenidate—Ill-defined disorder—Thalidomide—leprosy	0.00279	0.00279	CcSEcCtD
Methylphenidate—Anaemia—Thalidomide—leprosy	0.00278	0.00278	CcSEcCtD
Methylphenidate—Agitation—Thalidomide—leprosy	0.00277	0.00277	CcSEcCtD
Methylphenidate—Angioedema—Thalidomide—leprosy	0.00275	0.00275	CcSEcCtD
Methylphenidate—Malaise—Thalidomide—leprosy	0.00272	0.00272	CcSEcCtD
Methylphenidate—Vertigo—Thalidomide—leprosy	0.00271	0.00271	CcSEcCtD
Methylphenidate—Syncope—Thalidomide—leprosy	0.0027	0.0027	CcSEcCtD
Methylphenidate—Leukopenia—Thalidomide—leprosy	0.0027	0.0027	CcSEcCtD
Methylphenidate—Palpitations—Thalidomide—leprosy	0.00266	0.00266	CcSEcCtD
Methylphenidate—Loss of consciousness—Thalidomide—leprosy	0.00265	0.00265	CcSEcCtD
Methylphenidate—Cough—Thalidomide—leprosy	0.00263	0.00263	CcSEcCtD
Methylphenidate—Convulsion—Thalidomide—leprosy	0.00261	0.00261	CcSEcCtD
Methylphenidate—Hypertension—Thalidomide—leprosy	0.0026	0.0026	CcSEcCtD
Methylphenidate—Chest pain—Thalidomide—leprosy	0.00256	0.00256	CcSEcCtD
Methylphenidate—Myalgia—Thalidomide—leprosy	0.00256	0.00256	CcSEcCtD
Methylphenidate—Arthralgia—Thalidomide—leprosy	0.00256	0.00256	CcSEcCtD
Methylphenidate—Anxiety—Thalidomide—leprosy	0.00255	0.00255	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00255	0.00255	CcSEcCtD
Methylphenidate—Discomfort—Thalidomide—leprosy	0.00253	0.00253	CcSEcCtD
Methylphenidate—Dry mouth—Thalidomide—leprosy	0.00251	0.00251	CcSEcCtD
Methylphenidate—Confusional state—Thalidomide—leprosy	0.00248	0.00248	CcSEcCtD
Methylphenidate—Oedema—Thalidomide—leprosy	0.00246	0.00246	CcSEcCtD
Methylphenidate—Infection—Thalidomide—leprosy	0.00244	0.00244	CcSEcCtD
Methylphenidate—Shock—Thalidomide—leprosy	0.00242	0.00242	CcSEcCtD
Methylphenidate—Nervous system disorder—Thalidomide—leprosy	0.00241	0.00241	CcSEcCtD
Methylphenidate—Thrombocytopenia—Thalidomide—leprosy	0.00241	0.00241	CcSEcCtD
Methylphenidate—Tachycardia—Thalidomide—leprosy	0.0024	0.0024	CcSEcCtD
Methylphenidate—Skin disorder—Thalidomide—leprosy	0.00239	0.00239	CcSEcCtD
Methylphenidate—Hyperhidrosis—Thalidomide—leprosy	0.00238	0.00238	CcSEcCtD
Methylphenidate—Anorexia—Thalidomide—leprosy	0.00234	0.00234	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Thalidomide—leprosy	0.00224	0.00224	CcSEcCtD
Methylphenidate—Insomnia—Thalidomide—leprosy	0.00222	0.00222	CcSEcCtD
Methylphenidate—Paraesthesia—Thalidomide—leprosy	0.00221	0.00221	CcSEcCtD
Methylphenidate—Dyspnoea—Thalidomide—leprosy	0.00219	0.00219	CcSEcCtD
Methylphenidate—Somnolence—Thalidomide—leprosy	0.00218	0.00218	CcSEcCtD
Methylphenidate—Dyspepsia—Thalidomide—leprosy	0.00216	0.00216	CcSEcCtD
Methylphenidate—Decreased appetite—Thalidomide—leprosy	0.00214	0.00214	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Thalidomide—leprosy	0.00212	0.00212	CcSEcCtD
Methylphenidate—Fatigue—Thalidomide—leprosy	0.00212	0.00212	CcSEcCtD
Methylphenidate—Constipation—Thalidomide—leprosy	0.0021	0.0021	CcSEcCtD
Methylphenidate—Pain—Thalidomide—leprosy	0.0021	0.0021	CcSEcCtD
Methylphenidate—Feeling abnormal—Thalidomide—leprosy	0.00203	0.00203	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Thalidomide—leprosy	0.00201	0.00201	CcSEcCtD
Methylphenidate—Urticaria—Thalidomide—leprosy	0.00195	0.00195	CcSEcCtD
Methylphenidate—Abdominal pain—Thalidomide—leprosy	0.00194	0.00194	CcSEcCtD
Methylphenidate—Body temperature increased—Thalidomide—leprosy	0.00194	0.00194	CcSEcCtD
Methylphenidate—Hypersensitivity—Thalidomide—leprosy	0.00181	0.00181	CcSEcCtD
Methylphenidate—Asthenia—Thalidomide—leprosy	0.00176	0.00176	CcSEcCtD
Methylphenidate—Pruritus—Thalidomide—leprosy	0.00174	0.00174	CcSEcCtD
Methylphenidate—Diarrhoea—Thalidomide—leprosy	0.00168	0.00168	CcSEcCtD
Methylphenidate—Dizziness—Thalidomide—leprosy	0.00163	0.00163	CcSEcCtD
Methylphenidate—Vomiting—Thalidomide—leprosy	0.00156	0.00156	CcSEcCtD
Methylphenidate—Rash—Thalidomide—leprosy	0.00155	0.00155	CcSEcCtD
Methylphenidate—Dermatitis—Thalidomide—leprosy	0.00155	0.00155	CcSEcCtD
Methylphenidate—Headache—Thalidomide—leprosy	0.00154	0.00154	CcSEcCtD
Methylphenidate—Nausea—Thalidomide—leprosy	0.00146	0.00146	CcSEcCtD
